How to Help Your Patients Save Money on Trijardy XR: A Provider's Guide to Savings Programs

Trijardy XR's retail price of $550-600 per month (WAC) places it beyond the reach of many patients without insurance coverage or manufacturer assistance. Cost-related non-adherence is one of the most preventable drivers of poor diabetes outcomes. This guide equips prescribers with concrete strategies to help their patients access Trijardy XR at a reduced cost — and to know when a cost-effective alternative may serve the patient better.

Understanding the Cost Burden

Trijardy XR is a brand-name-only medication with no FDA-approved generic fixed-dose equivalent as of 2026. The wholesale acquisition cost (WAC) is approximately $550-600/month. Patients may face this cost in full if:

• They are uninsured
• Their plan places it on a high-tier formulary (Tier 4 or 5) with high coinsurance
• They are in the Medicare Part D deductible phase or prior to reaching their out-of-pocket maximum
• They have prior authorization or step therapy requirements that haven't yet been resolved

Option 1: Boehringer Ingelheim Co-Pay Savings Card (Commercially Insured Patients)

For commercially insured patients, the Boehringer Ingelheim co-pay savings program is the most powerful cost-reduction tool. Eligible patients may pay as little as $0/month for Trijardy XR. At the point of prescribing, take these steps to maximize enrollment:

• Provide the co-pay savings card with the prescription or have the patient download it before going to the pharmacy
• Verify the patient has commercial insurance (not Medicare, Medicaid, TRICARE, or other government programs — not eligible)
• Counsel patients about copay accumulator adjustment programs — some employers' insurance plans prevent the manufacturer savings from counting toward the annual deductible. This can create a significant mid-year cost surprise when the card limits are reached.
• Contact your Boehringer Ingelheim representative for current program terms and enrollment materials

Option 2: Patient Assistance Programs (Uninsured and Underinsured Patients)

For patients with insufficient or no insurance, Boehringer Ingelheim's Patient Assistance Program (PAP) can provide Trijardy XR at no cost to qualifying patients. Income eligibility guidelines (approximate, as of 2025):

• Individual: up to approximately $40,000/year
• Couple: up to approximately $60,000/year
• Family (larger households): up to approximately $100,000/year

To initiate enrollment:

1. Patient or staff calls 800-556-8317 or 866-316-7263
2. Provider completes a prescription attestation form
3. Patient provides income documentation
4. Approved patients receive medication directly by mail, typically within 2-4 weeks of approval

Option 3: Managing Insurance Prior Authorization and Step Therapy

Trijardy XR frequently requires prior authorization (PA) and may be subject to step therapy on commercial and Medicare Advantage plans. A proactive approach reduces patient cost and delay:

• Include clinical documentation upfront: A1C history, cardiovascular diagnosis, prior medications tried (and failed), current eGFR, and reason for the triple combination over simpler alternatives
• Document step therapy compliance: If the plan requires prior use of metformin ± a DPP-4 inhibitor, document previous prescriptions in the PA request
• Cite cardiovascular indication: Empagliflozin has Class I ADA and ACC/AHA guideline recommendations for patients with T2DM and established ASCVD — this is often a strong basis for medical necessity
• Request peer-to-peer review for urgent cases: Most commercial payers can arrange peer-to-peer within 24 hours for urgent PA requests, which often results in faster approval

Option 4: Formulary Exception Request

If Trijardy XR is not on a patient's formulary at all, a formulary exception may be requested. This requires a letter of medical necessity explaining why Trijardy XR is medically necessary over formulary alternatives. Key arguments to include:

• Established cardiovascular disease requiring empagliflozin specifically (CV mortality benefit not demonstrated with all SGLT2 inhibitors equally)
• Documented intolerance or contraindication to formulary alternatives
• Rationale for fixed-dose combination over separate medications (adherence, polypharmacy reduction, and demonstrated A1C improvement on prior components)

Option 5: When Cost Makes an Alternative the Right Clinical Choice

For patients who cannot access any of the above savings mechanisms and for whom cost is a genuine barrier to adherence, a cost-driven therapeutic switch may be warranted. Consider:

• Generic sitagliptin/metformin ER (generic Janumet XR) + Farxiga (dapagliflozin): Good glycemic equivalence for many patients; generic sitagliptin availability reduces DPP-4 component cost significantly
• Glyxambi + generic metformin ER: Preserves the empagliflozin/linagliptin combination; may have different formulary tier or PA requirements
• Farxiga + generic metformin ER: Cost-effective SGLT2 + biguanide combination; lacks DPP-4 component but well-tolerated and strongly evidence-based

Proactive Practice Workflow for Trijardy XR Prescriptions

Integrate these steps into your workflow at the point of prescribing:

1. Check insurance formulary tier and PA requirements before the patient leaves the office (most EHR e-prescribing tools now show formulary status in real time)
2. Provide manufacturer savings card or PAP enrollment instructions at point of prescribing
3. Use medfinder for providers to confirm pharmacy availability before routing the e-prescription, reducing calls from patients who can't find it
4. Recommend 90-day mail-order at initial prescribing for chronic-use patients — reduces both cost and availability disruption
5. Schedule adherence follow-up at 30 days: ask specifically if cost was a barrier to filling — and act on it before non-adherence becomes non-compliance

For clinical information on Trijardy XR availability and therapeutic substitution, see the Trijardy XR provider shortage brief.